Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $1.80M | $200K | $1.30M |
| Revenue growth | — | -88.9% | 550.0% |
| Operating income | -$219M | -$331M | -$135M |
| Operating margin | -12178.9% | -165724.0% | -10386.5% |
| Net income | -$241M | $1.69B | -$140M |
| Net margin | -13408.9% | 843786.0% | -10773.5% |
| EPS (diluted) | -$20.48 | $112.62 | -$9.04 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$193M | -$194M | -$130M |
| Capital expenditures | $4.59M | $2.60M | $31.0K |
| Free cash flow | -$198M | -$197M | -$130M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $278M | $153M | $124M |
| Total assets | $308M | $181M | $146M |
| Total liabilities | $264M | $47.2M | $138M |
| Long-term debt | $207M | $0.00 | $101M |
| Shareholders' equity | $43.5M | $134M | $7.99M |
| Retained earnings | -$614M | -$106M | -$246M |
| Shares (wtd avg diluted) | 11.8M | 15.0M | 15.5M |
Every figure is extracted from Inhibrx Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.